We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
5 peer-reviewed studies
What the evidence says
Most Zoledronate studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2007–2021 with a typical study size of 1,065 participants.
Based on 5 studies · 2 RCTs · 1,065 total participants
Confidence
LowBy outcome
1 study in the last 5 years
Yearly zoledronic acid after a hip fracture reduced clinical fractures and lowered all-cause mortality.
Lyles, Colón-Emeric, Magaziner, Adachi, Pieper, Mautalen · The New England journal of medicine (2007)
Zoledronate prevented fractures in patients with cognitive impairment presenting with hip fracture.
Prieto-Alhambra, Judge, Arden, Cooper, Lyles, Javaid · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014)
Bisphosphonates are reviewed for effects on lifespan beyond their skeletal action.
Center, Lyles, Bliuc · Bone (2020)
Zoledronic acid is reviewed for the treatment and prevention of osteoporosis.
Rizzoli · Therapeutic advances in musculoskeletal disease (2010)
All-cause mortality risk was examined in aged femoral intertrochanteric (hip) fracture patients.
Li, Zhang, Zhu, Yang, Wu, Jiang · Journal of orthopaedic surgery and research (2021)